Metabolomics analysis of three *Artemisia* species in the Tibet autonomous region of China

Xinyu Liu¹, Jinglong Wang²†, Enxia Huang¹, Bo Li¹, Shuhang Zhang¹, Weina Wang¹, Ziyu Guo¹, Kexin Wu¹, Yunhao Zhang¹, Baoyu Zhao¹ and Hao Lu¹*

Abstract

**Background:** The *Artemisia* species are widely distributed around the world, and have found important usage in traditional medicinal practice. This study was designed to investigate the metabolites of Tibetan *Artemisia* species and understand the metabolic pathways.

**Methods:** The metabolites from three *Artemisia* species in Tibet, were analyzed using LC–MS/MS. The differential metabolites were classified and analyzed by principal component analysis (PCA), partial least squares analysis and hierarchical clustering. KEGG Pathway enrichment analysis was used to identify the key metabolic pathways involved in the differential metabolites of three *Artemisia* species.

**Result:** The metabolites of three *Artemisia* species were analyzed. Under the positive ion mode in LC–MS/MS, 262 distinct metabolites were differentially detected from *Artemisia sieversiana* and *Artemisia annua*, 312 differential metabolites were detected from *Artemisia wellbyi* and *Artemisia sieversiana*, 306 differential metabolites were screened from *Artemisia wellbyi* and *Artemisia annua*. With the negative ion mode, 106 differential metabolites were identified from *Artemisia sieversiana* and *Artemisia annua*, 131 differential metabolites were identified from *Artemisia wellbyi* and *Artemisia sieversiana*, 133 differential metabolites were differentially detected from *Artemisia wellbyi* and *Artemisia annua*. The selected differential metabolites were mainly organic acids and their derivatives, ketones, phenols, alcohols and coumarins. Among these natural compounds, artemisinin, has the highest relative content in *Artemisia annua*.

**Conclusions:** This is the first reported attempt to comparatively determine the types of the metabolites of the three widely distributed *Artemisia* species in Tibet. The information should help medicinal research and facilitate comprehensive development and utilization of *Artemisia* species in Tibet.

**Keywords:** *Artemisia sieversiana*, *Artemisia wellbyi*, *Artemisia annua*, Non-targeted metabolomics, LC–MS/MS, Tibet

Background

*Artemisia* is a large genus of *Anthemideae* in the *Compositae* family. There are about 350 species in the world. The members of *Artemisia* are widely distributed in the temperate, frigid and subtropical regions of the northern hemisphere, with a few species distributed in the southern hemisphere [1]. It is well adapted in various environments and can survive in high altitude and extremely arid areas. *Artemisia* plants are mostly herbs, only a few are bushes or small shrubs, and most of them can be used as medicine and food for human consumption as well as animal feed [2, 3]. There are 186 species and 44 varieties of *Artemisia* plants in China, which are distributed throughout the country and widely used in traditional Chinese medicinal practice utilizing their properties of antibacterial, anti-inflammatory, and coagulant activity [5]. In addition, there are more than

*Correspondence: luhao@nwsuaf.edu.cn*
†Xinyu Liu and Jinglong Wang contributed equally to this work.
¹ College of Veterinary Medicine, Northwest A&F University, Yangling 712100, Shaanxi, China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
30 Artemisia plants distributed in grassland and desert areas. They are highly resistant to the adverse conditions and have potential ecological and economic value [6, 7]. They are important livestock feed, windbreak and sand-stabilizing plants in pastoral areas [8, 9].

Artemisia plant extracts contain polysaccharides, essential oils, organic acids, terpenes, flavonoids, with many of these components possessing the anti-inflammatory, immune-regulating, anti-tumor, anti-bacterial and anti-coagulant effects [10, 11]. Artemisinin drugs extracted from this genus of Artemisia annua have been demonstrated to be the highly effective anti-malarial therapeutics. The anti-cholera drug "Artemisia wormwood" for liver and gallbladder diseases also belong to this genus.

Presently, the types of metabolites of Artemisia plants and the differences in metabolites among these plants are not clear. In this study, we selected three Artemisia plants for metabolomics analysis using LC-MC/MS methodology to determine the metabolites of these Artemisia plants and analyze the differences in metabolites in order to understand the constituents of the 3 species of Artemisia in Tibet. This study will provide new evidence for the potential medicinal use of the three Tibetan Artemisia species and lay the foundation for further exploration of the active constituents, their metabolic pathways, and pharmacological mechanisms of action.

Results

Qualitative analysis of metabolites

The results are shown in the Additional file 1. In the negative ion mode, a total of 220 metabolites were identified from three Artemisia species. In the positive ion mode, a total of 535 metabolites were identified from three Artemisia species. The results showed that Artemisia plants contain polysaccharides, organic acids, flavonoids, terpenes, pigments, coumarin and other chemical components.

Principal component analysis (PCA)

PCA was used to distinguish the overall distribution trend between each two groups of samples (Fig. 1). As shown in Fig. 1A (a) and Fig. 1B (a), the samples of group D are all overlapped, and the correlation is good, while the Q group is mostly separated, and the degree of correlation is not as good as D.. There is no crossover between group D and group Q, which indicate that the difference between the two groups is relatively large, indicating that the metabolites between Artemisia sieversiana and Artemisia annua have a tendency to separate, and there are differences between groups. As shown in Fig. 1A (b) and Fig. 1B (b), the samples of group D are all overlapped, and the correlation is relatively good. There is no crossover between the D group and the Z group, which shows that the difference between the two groups is relatively large, indicating that the metabolites between Artemisia wellbyi and Artemisia sieversiana have a tendency to separate, and there are differences between groups. As shown in Fig. 1A (c) and Fig. 1B (c), the samples in group Q are all overlapped, and the correlation is better, while the Z group is mostly separated, and the correlation is not so good. There is no crossover between the Z group and the Q group, which shows that the difference between the two groups is relatively large, indicating that the metabolites between Artemisia wellbyi and Artemisia annua have a tendency to separate, and there are differences between groups.

Discriminant analysis of partial least squares (PLS-DA)

In the group (a) of Fig. 2A and Fig. 2B, the D group and the Q group are clearly separated, which shows that the metabolites between Artemisia sieversiana and Artemisia annua have a tendency to separate, which can explain the difference between the groups of Artemisia sieversiana and Artemisia annua is very large. In groups (b) of Fig. 2A and Fig. 2B, there is a clear separation between groups Z and D, demonstrating a trend towards separation of metabolites between Artemisia wellbyi and Artemisia sieversiana. The inter-group differences between Artemisia wellbyi and Artemisia sieversiana are very large. The clear separation between groups Z and Q in groups (c) of Fig. 2A and Fig. 2B demonstrates the tendency for metabolites to segregate between Artemisia wellbyi and Artemisia annua and the inter-group differences between Artemisia wellbyi and Artemisia annua are observable.

Differential metabolites analysis

The Variable Importance in the Projection (VIP) value of the first principal component of the PLS-DA model was used. The VIP value represents the contribution rate of the metabolite difference in different groups; the difference multiple (Fold Change, FC) represents each metabolism. The ratio of the mean value of the repeated quantitative values of all metabolites in the comparison group; combined with the p value of t-test to find the differentially expressed metabolites, set the threshold value to VIP > 1.0, the multiple of difference FC > 1.2 or FC < 0.833 and p-value < 0.05, and the selected different metabolites are shown in Table 1. The information of the different metabolites selected from the 3 species of Artemisia plants is in Additional file 2. Scopoletin was a representative differential metabolite in Artemisia sieversiana and Biochanin A was a representative differential metabolite in Artemisia wellbyi.
Comparing group D with group Q, in the positive ion mode, a total of 535 metabolites are identified. Among the 535 metabolites, 262 are different. That is, there are 262 differential metabolites between *Artemisia sieversiana* and *Artemisia annua*. Total 149 of differential metabolites are up-regulated among the 262 differentially regulated metabolites. In the negative ion mode, a total of 220 metabolites are identified, and 106 of these 220 metabolites are different. Total 68 of differential metabolites are up-regulated among the 106 differentially regulated metabolites.

Comparing group Z with group D, in the positive ion mode, a total of 535 metabolites are identified. Among these 535 metabolites, 312 are different. That is, there are 312 differences between *Artemisia wellbyi* and *Artemisia sieversiana* metabolites, of which the total number of differential metabolites that are up-regulated is 163, and the total number of differential metabolites that are down-regulated is 149; in the negative ion mode, a total of 220 metabolites are identified, and 131 of these 220 metabolites are different, that is, there were 131 differential metabolites screened between *Artemisia wellbyi* and *Artemisia sieversiana*. The total number of differential metabolites was 69 up-regulated and 62 were down-regulated.

Comparing group Z with group Q, in the positive ion mode, a total of 535 metabolites are identified. Among these 535 metabolites, 306 are different. That is, there are 306 differential metabolites between *Artemisia wellbyi* and *Artemisia sieversiana*. The total number of differential metabolites that are up-regulated is 163, and the total number of differential metabolites that are down-regulated is 149; in the negative ion mode, a total of 220 metabolites are identified, and 131 of these 220 metabolites are different, that is, there were 131 differential metabolites screened between *Artemisia wellbyi* and *Artemisia sieversiana*. The total number of differential metabolites was 69 up-regulated and 62 were down-regulated.

![Fig. 1 Principal Component Analysis. A: Positive ion mode (a) D vs Q principal component analysis (PCA) (b) Z vs D principal component analysis (PCA) (c) Z vs Q principal component analysis (PCA) B: Negative ion mode (a) D vs Q principal component analysis (PCA) (b) Z vs D principal component analysis (PCA) (c) Z vs Q principal component analysis (PCA). The horizontal and vertical coordinates PC1 and PC2 in the figure indicate the scores of the first and second ranked principal components respectively, the different coloured scatter points indicate samples from different experimental subgroups, and the ellipses are 95% confidence intervals (95% confidence ellipses cannot be shown when the number of biological replicates is less than 4). ("D" refer to *Artemisia sieversiana*. "Q" refer to *Artemisia annua*. "Z" refer to *Artemisia wellbyi")](image-url)
and *Artemisia annua*. Among them, the total number of differential metabolites that are up-regulated is 148, and the total number of differential metabolites that are down-regulated is 158; in negative ion mode, a total of 220 metabolites are identified, and 133 of these 220 metabolites are different, namely *Artemisia wellbyi*. A total of 133 differential metabolites were screened from *Artemisia annua*, of which 59 were up-regulated and 74 were down-regulated.

Comparing the difference folds of the different metabolites in the samples of *Artemisia sieversiana* and *Artemisia annua*, as shown in Table 2 are the top 20 differentially expressed metabolic components in

### Table 1

| Compared Groups | Num. of Total Ident | Num. of Total Sig | Num. of Sig. Up | Num. of Sig. down |
|-----------------|---------------------|------------------|-----------------|-------------------|
| D vs. Q_neg     | 220                 | 106              | 38              | 68                |
| D vs. Q_pos     | 535                 | 262              | 113             | 149               |
| Z vs. D_pos     | 535                 | 312              | 163             | 149               |
| Z vs. D_neg     | 220                 | 131              | 69              | 62                |
| Z vs. Q_pos     | 533                 | 306              | 148             | 158               |
| Z vs. Q_neg     | 220                 | 133              | 59              | 74                |

*D* refers to *Artemisia sieversiana*; *Q* refers to *Artemisia annua*; *Z* refers to *Artemisia wellbyi*
the difference fold change. Compared with **Artemisia annua**, clear differences can be seen in **Artemisia sieversiana** regarding the contents of Clotrimazole, Deoxyinosine, Methyleugenol, Scopoletin, Parthenin, Daidzin, Oxymorphone, Gibberellin A3 Nivalenol and several other compounds.

Differentially present metabolites in the samples of **Artemisia sieversiana** and **Artemisia wellbyi** were compared, and the top 20 differential metabolites in terms of levels of presence are shown in Table 3. Compared to **Artemisia sieversiana**, **Artemisia wellbyi** showed a higher levels of 1-Naphthylamine, Isodehydrocostus lactone, Anastrozole, Pseudoivalin, Etodolac, Prostaglandin I2, Baicalin,Cyanidin 3-O-(6-O-malonyl-beta-D-glucoside), Quercetin, Cyanidin 3-glucoside, Biochanin A, Telmisartan were different in content.

The different metabolites in the samples of **Artemisia wellbyi** and **Artemisia annua** were compared. Table 4 shows the top 20 differentially expressed metabolic components with differences in fold change. Compared with **Artemisia annua**, **Artemisia wellbyi** is more Clotrimazole, 2-Pyrocatechuic acid, Fenfluramine, Deoxyinosine, 6-Tuliposide A, Chlorpheniramine, Quadroline, Tectorigenin, Biochanin A, Quercetin 3-(6-malonyl-glucoside), Cyanidin 3-O-(6-O-malonyl-beta-D-glucoside).

Volcano map of differential metabolites

The volcano chart can visually display the overall distribution of different metabolites, and the results are shown in Fig. 3. Figure 3A and 3B visually show the significantly different metabolites between the three **Artemisia** plants. The overall and visual display of the specific metabolites of each group and their differences can be used as a functional analysis of metabolic pathways. As shown in the Fig. 3, red is up-regulated, green is down-regulated, and gray is not occurring, that is, the metabolites is no difference.

Cluster analysis of differential metabolites

A hierarchical clustering analysis is performed on all the difference metabolites between the obtained comparison pairs, and the relative quantitative values of the difference metabolites are normalized and converted and clustered. As shown in Fig. 4.

Different colored areas in the figure represent differentially clustered groups. Metabolites with similar expression patterns in the same group will be clustered together suggesting similar or identical biological processes. It can be seen intuitively from the positive ion pattern that the upper part of the Z group is red, and the upper part of the D and Q groups are blue, indicating that there are many different metabolites in the **Artemisia wellbyi** group that

| ID     | name                        | formula           | mz      | rt      | FC      |
|--------|-----------------------------|-------------------|---------|---------|---------|
| M345TS31 | Clotrimazole        | C_{22}H_{17}ClN_{2} | 345.116045 | 531.209 | 0.000675967 |
| M137T378 | 2-Pyrocatechuic acid  | C_{7}H_{6}O_{4}   | 137.0230757 | 377.943 | 0.001085703 |
| M233T835 | Deoxyinosine          | C_{10}H_{12}N_{4}O_{4} | 233.1535352 | 835.184 | 0.002761027 |
| M197T515 | Vanillylmandelic acid | C_{9}H_{10}O_{5}  | 197.1168458 | 515.317 | 0.003251957 |
| M176T418 | Citrulline           | C_{6}H_{14}O_{3}  | 176.1067365 | 418.3865 | 0.004265399 |
| M303T741 | 4-Coumaryloshikimate  | C_{10}H_{16}O_{5} | 303.0852229 | 740.6695 | 0.004272602 |
| M179T831 | Methyleugenol        | C_{11}H_{16}O_{5} | 179.1061699 | 830.604 | 0.005805587 |
| M191T543 | Scopoletin           | C_{10}H_{18}O_{2} | 191.0330383 | 543.054 | 0.006373881 |
| M95T359  | Dimethyl sulfone      | C_{2}H_{4}O_{5}S | 95.06065372 | 359.041 | 0.007144107 |
| M277T665 | Maprotiline           | C_{9}H_{12}O_{2}  | 277.1768268 | 665.0745 | 0.007563324 |
| M267T718 | Magnolol             | C_{10}H_{14}O_{2} | 267.1367803 | 718.218 | 61.83611633 |
| M165T774 | 3-Methyloxanthine     | C_{11}H_{16}O_{2} | 165.0904348 | 774.339 | 66.21775279 |
| M185T541 | Sebacic acid         | C_{10}H_{14}O_{4} | 185.1169568 | 540.671 | 76.33432461 |
| M245T656 | Parthenin            | C_{10}H_{16}O_{2} | 245.1169082 | 650.867 | 84.99636582 |
| M491T560 | Malvidin 3-glucoside | C_{22}H_{20}O_{8} | 491.1227365 | 560.099 | 185.2503201 |
| M417T671 | Daidzin              | C_{21}H_{20}O_{6} | 417.1512452 | 670.8345 | 238.9987532 |
| M295T740 | Nivalenol            | C_{11}H_{12}O_{2} | 295.1165284 | 740.449 | 248.6474766 |
| M195T534 | 2-Amino-2-deoxy-D-gluconate | C_{6}H_{10}N_{4}O_{6} | 195.1704612 | 534.474 | 395.244568 |
| M302T583 | Oxyomorphine         | C_{10}H_{14}N_{2}O_{4} | 302.1378483 | 582.511 | 434.4695806 |
| M345T468 | Gibberellin A3       | C_{10}H_{20}O_{9} | 345.1331023 | 467.938 | 1064.542676 |

*D* refer to **Artemisia sieversiana**; *Q* refer to **Artemisia annua**
### Table 3  Significant analysis results of different metabolites (Z vs D)

| ID     | name                                         | formula | mz       | rt      | FC   |
|--------|----------------------------------------------|---------|----------|---------|------|
| M195T534 | 2-Amino-2-deoxy-D-gluconate                   | C₆H₁₃NO₆ | 195.1740612 | 534.474 | 0.002438344 |
| M143T420 | 1-Naphthylamine                               | C₁₀H₉N   | 143.0692372 | 420.013 | 0.003517768 |
| M18ST541 | Sebacic acid                                  | C₁₀H₁₈O₄  | 185.1169568 | 540.671 | 0.004686047 |
| M231T828 | Isoheptacoside lactone                       | C₁₄H₂₁O₂  | 231.1359405 | 827.521 | 0.005209893 |
| M290T357 | Argininosuccinic acid                         | C₁₈H₂₈N₆O₆ | 290.1230746 | 357.2365 | 0.0080221 |
| M232T600_2 | Butyryl-L-carnitine                           | C₁₅H₂₀N₂O₄ | 232.1373531 | 599.751 | 0.009387972 |
| M294T416 | Anastrozole                                   | C₁₉H₂₈N₆O₄ | 294.1685475 | 415.5425 | 0.011303827 |
| M248T604 | Pseudovalin                                   | C₁₄H₂₀O₅  | 248.1352512 | 604.322 | 0.011939235 |
| M288T604 | Etofalcet                                     | C₁₁H₂₁NO₄ | 288.1586762 | 604.407 | 0.015893255 |
| M352T647 | Prostaglandin i2                              | C₂₀H₂₃N₂O₂ | 352.2475222 | 646.51 | 0.01739463 |
| M461T444 | Luteolin 7-O-glucuronide                      | C₁₂H₁₄O₂  | 461.0705682 | 444.0825 | 0.017752218 |
| M299T771 | 2-Methoxyestrone                              | C₁₄H₂₂O₄  | 299.1644825 | 771.377 | 0.017741889 |
| M445T468 | Baicalin                                       | C₁₅H₂₁NO₃ | 445.0745556 | 467.977 | 0.017348701 |
| M248T604 | Pseudovalin                                   | C₁₅H₂₀O₅  | 248.1352512 | 604.322 | 0.011939235 |
| M288T604 | Etofalcet                                     | C₁₁H₂₁NO₄ | 288.1586762 | 604.407 | 0.015893255 |
| M352T647 | Prostaglandin i2                              | C₂₀H₂₃N₂O₂ | 352.2475222 | 646.51 | 0.01739463 |

*“Z” refer to Artemisia wellbyi; “D” refer to Artemisia sieversiana*

### Table 4  Results of significant analysis of differential metabolites (Z vs Q)

| ID     | name                                         | formula | mz       | rt      | FC   |
|--------|----------------------------------------------|---------|----------|---------|------|
| M345T531 | Clotrimazole                                 | C₂₂H₁₇ClN₂ | 345.116045 | 531.209 | 0.001026279 |
| M137T738 | 2-Pyrocathechuic acid                         | C₆H₁₄O₄  | 137.0230757 | 377.943 | 0.001986427 |
| M113T365 | 2-Heptanone                                   | C₆H₁₄O  | 113.0951658 | 365.093 | 0.00243751 |
| M145T383 | 4-Guanidinobutanoic acid                      | C₅H₁₁N₃O₂  | 145.0844448 | 383.315 | 0.00275377 |
| M232T557 | Fenfluramine                                  | C₁₂H₁₆F₃N  | 232.1328328 | 557.387 | 0.004482499 |
| M176T418 | Citriline                                     | C₁₅H₁₈N₃O₃  | 176.1067365 | 418.385 | 0.004884859 |
| M233T835 | Deoxyninosine                                 | C₁₂H₁₄N₄O₄  | 233.1535352 | 835.184 | 0.005626588 |
| M278T550 | 6-Tuliposide A                                | C₁₁H₁₈O₆  | 278.1051472 | 549.635 | 0.00571858 |
| M275T700 | Chlorpheniramine                              | C₁₅H₁₆N₄O₆  | 275.1247371 | 700.007 | 0.006418824 |
| M249T783 | Quadrone                                      | C₁₁H₁₂O₃  | 249.1472448 | 783.0895 | 0.007130025 |
| M329T719 | Cynaropicrin                                  | C₁₅H₂₀O₆  | 329.1375137 | 619.393 | 0.007260237 |
| M267T718 | Magnolol                                      | C₁₈H₁₈O₆  | 267.1367803 | 718.218 | 0.007935082 |
| M311T835 | (E)-3-(4-Hydroxyphenyl)-2-propenal            | C₁₉H₁₄O₆  | 311.0486872 | 835.128 | 0.006043727 |
| M300T777 | Tectorigenin                                  | C₁₉H₁₈O₆  | 300.0571363 | 777.242 | 0.007961333 |
| M609T478 | Kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside | C₁₇H₁₈O₁₆ | 609.148457 | 478.401 | 0.007961333 |
| M495T661 | Telmisartan                                  | C₁₅H₂₀O₃  | 495.2225081 | 660.986 | 0.013763757 |
| M449T412 | Cyanidin 3-glucoside                          | C₂₁H₂₁O₁₁  | 449.1064872 | 1282.28964 | 0.015641949 |
| M285T780 | Biochanin A                                   | C₁₆H₁₂O₅  | 285.075064 | 779.795 | 0.015893255 |
| M285T780 | Biochanin A                                   | C₁₆H₁₂O₅  | 285.075064 | 779.795 | 0.015893255 |
| M285T780 | Biochanin A                                   | C₁₆H₁₂O₅  | 285.075064 | 779.795 | 0.015893255 |
| M285T780 | Biochanin A                                   | C₁₆H₁₂O₅  | 285.075064 | 779.795 | 0.015893255 |

*“Z” refer to Artemisia wellbyi; “Q” refer to Artemisia annua*
are highly expressed, while the expression levels in *Artemisia annua* and *Artemisia sieversiana* group are relatively low.

**Wayne analysis of different metabolites**

In the positive ion mode, the number of different metabolites of different species identified by the multivariate statistical method is 125 (Fig. 5). The number of different metabolites screened by *Artemisia sieversiana* compared with *Artemisia annua* and the different metabolites selected from *Artemisia wellbyi* is 185, the number of different metabolites selected by *Artemisia wellbyi* is the same as that of *Artemisia sieversiana*. The number of different metabolites screened by *Artemisia wellbyi* compared with *Artemisia annua* is 226, the number of different metabolites screened by *Artemisia wellbyi* compared with *Artemisia annua* is the same species. The number is 172.

In the negative ion mode, the number of different metabolites of different species identified by multivariate statistical methods is 46. The number of different metabolites screened by *Artemisia sieversiana* compared with *Artemisia annua* and the different metabolites screened by *Artemisia wellbyi* is 67, the number of different metabolites selected by *Artemisia wellbyi* is the same as that of *Artemisia annua*. The number of different metabolites selected from *Artemisia wellbyi* compared with *Artemisia annua* is 101, the number of different metabolites selected from *Artemisia sieversiana* compared with *Artemisia annua* is the same type. The number is 71.
Fig. 4 Cluster Analysis of Differential Metabolites. Clustering heat map of total differential metabolites (the upper frame is the grouped heat map, the lower frame is the sample heat map; each frame is the first picture is the positive ion mode, the second picture is the negative ion mode). The vertical direction is the clustering of samples, and the horizontal direction is the clustering of metabolites. The shorter the cluster branches, the higher the similarity. The relationship between the clustering of metabolite content between groups and samples can be seen through horizontal comparison. ('D' refer to Artemisia sieversiana. 'Q' refer to Artemisia annua. 'Z' refer to Artemisia wellbyi)

Fig. 5 Wayne Analysis of Different Metabolites of Different Species. A: Venn diagram of different metabolites of different species in positive ion mode. B: Venn diagram of different metabolites of different species in negative ion mode. ('D' refer to Artemisia sieversiana. 'Q' refer to Artemisia annua. 'Z' refer to Artemisia wellbyi)
KEGG pathway analysis of the metabolites

All the information on the metabolic pathways enriched by the differential metabolites detected in the 3 species of *Artemisia* is listed in Additional file 3. The significance analysis of KEGG can determine the main biological functions performed by the different metabolites. KEGG Pathway enrichment results of different metabolites are shown in Additional file 3. In the positive ion mode, 548 differential metabolites of D vs Q are annotated into metabolic pathways, 741 differential metabolites of Z vs D are annotated into metabolic pathways, and 631 differential metabolites of Z vs Q are annotated into metabolic pathways. In the metabolic pathway, the analysis showed that some metabolites can participate in multiple metabolic pathways, and multiple metabolic pathways are consistent among the comparison groups. In the negative ion mode, D vs Q has 392 differential metabolites annotated into the metabolic pathway, Z vs D has 532 differential metabolites annotated into the metabolic pathway, and Z vs Q has 510 differential metabolites are annotated into the metabolic pathway. The analysis showed that some metabolites can participate in multiple metabolic pathways, and multiple metabolic pathways are consistent among the comparison groups.

KEGG enrichment bubble chart

The enriched differentially expressed metabolites in KEGG pathway analysis also presented in bubble chart (only the results of top 20) are shown in Fig. 6A, 6B (Fig. 6).

The differential metabolites of *Artemisia sieversiana* and *Artemisia annua* (D vs Q) are enriched in the Linoleic acid metabolism, Monoterpenoid biosynthesis and Lysine biosynthesis pathway. The differential metabolites of *Artemisia wellbyi* and *Artemisia sieversiana* (Z vs D) are enriched in the Styrene degradation and Isoquinoline alkaloid biosynthesis pathway. The differential metabolites of *Artemisia wellbyi* and *Artemisia annua* (Z vs Q) are enriched in the Styrene degradation and Monoterpenoid biosynthesis pathway.

The significant enrichment of these three species of *Artemisia* on these pathways is helpful to understand the metabolic pathways of *Artemisia* plants and their intermediate metabolites, which lays the foundation for their biological research.

Artemisinin content of three *Artemisia* plants

Based on the detection results of non-targeted metabolomics, we detected artemisinin from three different *Artemisia* plants, and through screening, we found that artemisinin is an important differential metabolite. Figure 7A is the secondary spectrum of artemisinin obtained from three *Artemisia* plants in non-targeted metabolomics.

Having found that artemisinin is an important differential metabolite, we then used high-phase liquid chromatography combined with mass spectrometry to target the artemisinin content in these three *Artemisia* plants. The standard curve was drawn according to the calculated regression equation: \( Y = 500.74237X + 1551.22512 \) (R=0.99980). The concentration of artemisinin in *Artemisia sieversiana* is 3.545±1.202×10⁵µg/g. The concentration of artemisinin in *Artemisia wellbyi* is 4.799±2.544×10⁵µg/g. The concentration of artemisinin in *Artemisia annua* is 5.713±0.385×10⁵µg/g. Compared with *Artemisia annua*, the content of artemisinin in *Artemisia wellbyi* and *Artemisia sieversiana* was lower than that in *Artemisia annua* (Fig. 7B).

Discussion

In this study, the metabolomics of three representative species of *Artemisia* in blooming stage in Tibet were analyzed by metabolomic technology. The results of metabolite analysis showed that all three *Artemisia* plants contained fatty acids, glycerophospholipids, amino acids, sugars, nucleotides, phenolamines, organic acids, coumarins, catechins, vitamins, indole, and hydroxycinnamic acid. The metabolites of *Artemisia annua* are significantly different. Daidzin has a unique effect on breast cancer [12], prostate cancer [13], heart disease [14], cardiovascular disease [15] and other diseases [16]. Scopoletin has been shown to have anti-inflammatory effects [17], anti-tumor effects as well as analgesic effects [18–22]. We study the differential metabolites in *Artemisia wellbyi*. Quercetin has been found to have multiple biological activities, such as antioxidant [21], antiviral [22], and anti-inflammatory effects [23, 24]. Baicalin has significant biological activity. It has antibacterial, diuretic, anti-inflammatory, cholesterol-lowering, anti-thrombosis, relief of asthma, detoxification, and hemostasis [25, 26]. The pharmacological effects of these important metabolites are consistent with those recorded in the published literature [27, 28].

We use LC–MS to target detection of artemisinin content in 3 species of *Artemisia* plants. This study found that artemisinin is present in the three representative *Artemisia* plants, *Artemisia sieversiana*, *Artemisia wellbyi* and *Artemisia annua*, collected from Tibet. *Artemisia annua* contains the highest concentration of artemisinin, with an average value of 57,130 µg/g, the second is *Artemisia wellbyi* with an artemisinin content of 479.93 µg/g, the last is *Artemisia sieversiana*, its content is 354.47 µg/g. Xiang et al. [29] established a quick and easy UPLC-UV method for the detection of artemisinin, and tested
the content of artemisinin in *Artemisia annua* from different producing areas, and found that the artemisinin content of *Artemisia annua* from Chongqing City was as high as 10,000.4 µg/g. Cheng et al. [30] used UPLC-MS/MS detection to compare the artemisinin content of *Artemisia annua* from different sources, the results found that the origin of *Artemisia annua* with higher artemisinin content was Yunnan province, and the content was 3810.597 µg/g, followed by Hainan province, with an average of 3702.952 µg/g. By comparison, it is found that the artemisinin content of *Artemisia annua* in Tibet is the highest compared to other provinces, which indicates that as a traditional Tibetan plant of the genus *Artemisia*, *Artemisia annua* has properties of antibacterial, antitumor, antiviral, anti-inflammatory and these pharmacological properties may have important potential medicinal value.

Tibetan medicine is used for anti-inflammatory, visceral bleeding and so on [31]. *Artemisia sieversiana* is also a traditional herbal medicine used by Tibetan and Mongolian medicine. It mainly contains chemical components such as flavonoids, lignins, sesquiterpenes and volatile oils. The medicinal work "Compendium of Materia Medica" mentioned *Artemisia selengensis* and the
Artemisia sphaerocephala mentioned in "Shen Nong Materia Medica" are all Artemisia sieversiana [32, 33]. Artemisia sieversiana also has certain medicinal value. According to the records in "The Dictionary of Traditional Chinese Medicine" [34], Artemisia sieversiana has a sweet and flat taste, and it mainly treats wind-cold dampness, jaundice, heat dysentery, scabies and malignant sores.

In summary, our results show that Tibetan Artemisia plants have broad potential for medicinal value. They are
the dominant plants in Tibet’s alpine desert grasslands and are also potentially important forage and medicinal plant resources. Moreover, they still play an important role in the ecological protection and economic development of Tibet’s grassland. As a plant with both medicinal and edible value, Artemisia can also be developed as a functional food at the same time as a high-quality feed for livestock to improve vitality and disease resistance. In future, it is necessary to study the transcriptomics of the genes in these plants to understand their regulation in the synthesis of artemisinin in the three Artemisia plants and to transform them by genetic engineering technology to obtain high-yield artemisinin varieties, which can effectively solve the shortage of artemisinin sources.

Conclusions
This study is based on LC–MS/MS technology to qualitatively determine the differential metabolites of 3 species of Artemisia in Tibet. The types of differential metabolites screened out are mainly organic acids and their derivatives, ketones, phenols, alcohols and coumarins. Among them, artemisinin, as a representative differential metabolite, has the highest relative content in Artemisia annua. The content is 5.713±0.385×10⁷µg/g. The key metabolic pathways involved in the differential metabolites analyzed by KEGG enrichment are Linoleic acid metabolism, Monoterpenoid biosynthesis and Isoquinoline alkaloid biosynthesis. This study profiled the differential metabolites of the three Artemisia plants in Tibet, provided new evidence for their medicinal research, and opened up new ideas for the comprehensive development and utilization of Artemisia plants in Tibet.

Methods
Plant material
Artemisia sieversiana, Artemisia wellbyi and Artemisia annua were collected in Jinbei, Caina Township, Qushui County, Lhasa City, Tibet Autonomous Region in July 2019. The wild samples in this experiment was permitted by Lhasa Forestry and Grassland Administration. Permission was not necessary for collecting these species, which have not been included in the list of national key protected plants. Te formal identification of the plant material was undertaken by Professor Zhaoyang Chang, College of Life Science, Northwest A&F University. The voucher specimens of Artemisia sieversiana, Artemisia wellbyi and Artemisia annua were deposited at Herbarium, Institute of Botany, Chinese Academy of Sciences (voucher number PE01890226,PE01890481,PE01997408). These plants were taken from each sampling site with a size of 10 m × 10 m, and 9 plants were sampled along the diagonal, for a total of 27 samples. All samples were dried, crushed, passed through a 40-mesh sieve (with an aperture of 0.425 mm), put into a paper bag, and stored in a desiccator at room temperature for later use. One g each of 27 samples were wrapped in tin foil, snap frozen in liquid nitrogen for storage, transported in dry ice to Beijing Tiangen Technology Co., Ltd. for analysis.

Chemical reagents and instruments
Methanol (Merck, Germany), formic acid (ROE, USA), ammonium acetate (Honeywell, USA), and the Mili-Q ultrapure water system comes from Milipore Company (Massachusetts, USA), pipette (Thermo company, USA), freeze dryer, vacuum centrifugal concentrator (Christ company, Germany), centrifuge, mixer (Eppendorf company, Germany), high-speed disperser (IKA company, Germany), 0.22 μm filter membrane (Agilent Company, USA), CPA224S electronic analysis.

Experimental sample
The 27 plant samples were divided into 3 groups according to 3 different kinds of Artemisia plants, the first group "Artemisia sieversiana", was indicated by the letter "D"; the second group "Artemisia annua", was indicated by the letter "Q"; and the third group "Artemisia wellbyi", was marked by the letter "Z". The comparisons between the samples in the group are respectively denoted as D vs Q, Z vs Q, Z vs D, where D vs Q represents the metabolite comparison between "Artemisia sieversiana" and "Artemisia annua". There were 9 samples in each group, and 3 biological replicate experiments were performed respectively. Quality control samples (QC) were prepared by mixing equal amounts of three Artemisia extracts in three replicates and were treated and tested in the same way as the analytical samples, with one QC sample inserted in every 10 analytical samples tested during instrumental testing to investigate the stability and reproducibility of the entire analytical process.

Metabolite extraction
A 100 mg of liquid nitrogen ground tissue sample was placed in an EP tube, 500 µL of 80% methanol aqueous solution containing 0.1% formic acid was added, vortexed, left to stand in an ice bath for 5 min, and then centrifuged at 15,000 rpm, at 4 °C for 10 min. The supernatant (100µL) was diluted with mass spectrometry grade water to 53% methanol, and placed in a centrifuge tube at 15,000 g, 4 °C for 10 min. The supernatant was collected and injected into LC–MS for analysis. An equal volume of each sample was mixed as QC samples. The blank sample was replaced by aqueous 53% methanol solution containing 0.1% formic acid. The pretreatment process is the same as that of the experimental sample.
**Chromatographic conditions**

The chromatography column and conditions are as follows: Chromatographic column: Hyperil Gold column (C18); column temperature: 40 °C; flow rate: 0.2 mL/min; positive mode: mobile phase A: 0.1% formic acid; mobile phase B: methanol; negative mode: mobile phase A: 5 mM ammonium acetate, pH 9.0; mobile phase B: methanol (2) Elution gradient: 98:2 (V/V) at 0 min, 98:2 (V/V) at 1.5 min, 0:100 (V/V) at 12.0 min, 0:100 (V/V) at 14 min, 98:2 (V/V) at 14.1 min, and 17.0 min for 98:2 (V/V).

**Mass spectrometry conditions**

Scan range selection was m/z 70–1050 ESI source settings are as follows: Spray Voltage: 3.2 kV; Sheath gas flow rate: 35arb; Aux Gas flow rate: 10arb; Capillary Temp: 320 °C. Polarity: positive; negative; MS/MS secondary scan is data-dependent scans.

**Data processing and analysis**

The LC–MS raw data (.raw) files were imported into the CD search software to perform simple screening of retention time, mass-to-charge ratio, and then peak alignment for different samples according to retention time deviations of 0.2 min and massed deviations of 5 ppm were performed. Peak extraction was performed according to the set mass deviation of 5 ppm, signal intensity deviation of 30%, signal-to-noise ratio 3, minimum signal intensity of 100,000 and at the same time the peak area was quantified. The molecular formula of peak and fragment ions was predicted and compared with mzCloud, mzVault and MassList databases. The blank sample was used to remove background ions.

The peaks obtained from all experimental samples were subjected to UV processing and then the data were subjected to PCA analysis (Principal component analysis, PCA) which was used to reduce the dimensionality of metabolite variables through linear combination according to a certain weight, to generate new characteristic variables, and to classify them based on the similarity of the main new variables (principal components) to reflect the overall sample of each group. In order to highlight the differences between the groups and facilitate the subsequent search for different metabolites, the supervised discriminant analysis statistical method was used for partial least square regression PLS-DA, and the PLS-DA model of each comparison group. After sevenfold cross-validation (seven times) cyclic interactive verification, when the number of biological replicates of the sample was n ≤ 3, it is the model evaluation parameters (R2, Q2) obtained by k=2n). If R2 and Q2 are closer to 1, the model was more stable. To analyze the metabolic patterns of metabolites under different experimental conditions, all the different metabolites between the obtained comparison pairs were clustered into classes for metabolites with the same or similar metabolic patterns for hierarchical clustering analysis. The KEGG Pathway was taken as the unit, hypergeometric test was applied, p-value values were calculated. With P-value ≤ 0.05 as the threshold, the KEGG term that meets this condition was defined as the KEGG term that was significantly enriched in the differential metabolites. The pathways enriched in differential metabolites were determined comparing with the background of all identified metabolites.

**Abbreviations**

KEGG: Kyoto Encyclopedia of Genes and Genomes; PC1: First principal component; PCA: Principal component analysis; PLS-DA: Discriminant Analysis of Partial Least Squares; LC–MS/MS: Liquid chromatography-tandem mass spectrometry; VIP: Variable importance in projection.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12870-022-03513-z.

**Acknowledgements**

We sincerely thank Texas A&M University, Professor Yanan Tian for his assistance in the English language of the manuscript, and thank Xuemei Li for technical help with metabolomics analysis.

**Authors’ contributions**

H.L., J.W. and B.Z. contributed to the conception of the focus for the study. X.L., E.H., B.L., S.Z., W.W., and Z.G. performed the experiments. K.W. and Y.Z. analyzed the data. X.L. and H.L. contributed to the compilation of all sections, figure and table design, and wrote the first draft of the manuscript. All authors contributed to revision, read and approved the submitted version of the manuscript.

**Funding**

This work was supported by the grants from the key research and development projects of Tibet Autonomous Region (No. XZ201902NB01), the National Natural Science Foundation of China (No. 32072929), the above funding was used for the design of the study and collection, analysis, and interpretation of data in writing the manuscript.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The experiments did not involve endangered or protected species. The data collection of plants was carried out with permission of related institution, and complied with national or international guidelines and legislation.

**Consent for publication**

Not applicable.
References

1. Tan RX, Zheng WF, Tang HQ. Biologically active substances from the genus Artemisia Planta Med. 1998;64:295–302.

2. Lin YR. On the flora of the genus Artemisia in the world. Plant Res. 1995;15:31–37.

3. Yue YX, Shi BL, Zhang PF, Su JL, Li K, Yan SM. Research progress on the biological effects of Artemisia plants on animals. Chin J Anim Hub. 2015;51:79–82.

4. Dib I, Alaoui-FarissBFEEl. Artemisia campestris L: Review on taxonomical aspects, cytogeography, biological activities an bioactive compounds. Biomed Pharmacother. 2019;109:1884–906.

5. Ferreira JFS, Simon J, Janick J. Artemisia annua: botany, horticulture, pharmacology. Hor Rev. 1997;19:319.

6. Jastrzebska E, Wadas E, Daszkiewicz T. Nutritional value and health-promoting properties of mares milk. Czech J Anim Sci. 2017;62:511–8.

7. Du JQ. Layout and countermeasures for the development of Tibetan traditional Chinese medicinal materials industry with plateau characteristics. Gansu Sci Technol. 2015;3:13–4.

8. Cui NR. The second volume of Xinjiang’s main forage flora. Urumqi: Xinjiang Science and Technology Publishing House; 1994. p. 262–73.

9. Li HL, Zhang AD, Qing GL, Mu Z, Sun J. Current status and prospects of research and utilization of Artemisia sphaerocephala. Anim Hub and Feed Sci. 2014;35:46–8.

10. Habib M, Waheed I. Evaluation of anti-nociceptive anti-inflammatory and antipyretic activities of Artemisia scoparia hydromethanolic extract. J Ethnopharmacol. 2013;145:18–24.

11. Wang XH, Ma MH, Zhang JT, Huang J, Nian H. Research progress on the pharmacological effects of Artemisia annua. Chin J Mod App Pharm. 2018;35:781–5.

12. Applegate CC, Roweles JL, Ranard KM, Jeon S, Erdman JW. Soy consumption and the risk of prostate cancer: An updated systematic review and meta-analysis. Nutrients. 2018;10:40.

13. Dai WQ, Wang F, He L, Lin CL, Wu SM, Chen P, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT1. Mol Carcin. 2015;54:301–11.

14. Crouse JR, Morgan T, Terry JS, Ellis J, Vitolins M, Burke GL. Arandomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 1999;159:1070–6.

15. Teed HJ, Mcgrath BP, Desilva L, Cehun M, Fassoulakis A, Chalme-Napimoga JT, et al. The flavonoid quercetin inhibits titanium dioxide (TiO2)-induced chronic arthritis in mice. J Nutr Biochem. 2018;53:81.

16. Wei J, Bhatt S, Chang LM. Isoflavones, genistein and daidzein, regulate mucosal immune response by suppressing dendritic cell function. PLoS ONE. 2012;7:47979.

17. Dou Y, Tong B, Wei Z, Xia YF, Dai Y. Scopoletin suppresses IL-6 production from fibroblast-like synovocytes of adjuvant arthritis rats induced by IL-1β stimulation. Int Immunobiol. 2013;17:1037–43.

18. Schimmer O. Coumarin derivatives as protective agents against the cytotoxic and mutagenic effect of 5-methoxypsoralen and UV-A in Chloamydomonas reinhardtii. Planta Med. 1984;50:316–9.

19. Marshall ME, Conley D, Hollingsworth P, Brown S, Thompson JS. Effects of coumarin (1,2-benzopyrone) on lymphocyte, natural killer cell, and monocyte functions in vitro. J Biol Res Med. 1989;8:70–85.

20. Lee KH, Chai HB, Tamez PA, Pezzuto JM, Cordell GA, Win KK, et al. Biologically active alkylated coumarins from koeaya assamica. Phyto Chem. 2003;64:535–41.

21. Mehrbod P, Hudy D, Shyntum D, Markowski J, Los MJ, Ghavami S. Quercetin as a Natural Therapeutic Candidate for the Treatment of Influenza Virus. Biomolecules. 2020;11:10.

22. Borghi SM, Mzokami SS, Pinho-Ribeiro FA, Fattori V, Crespigo J, Clemente-Napimoga JT, et al. The flavonoid quercetin inhibits titanium dioxide (TiO2)-induced chronic arthritis in mice. J Nutr Biochem. 2018;53:81.

23. Borghi SM, Mzokami SS, Pinho-Ribeiro FA, Fattori V, Crespigo J, Clemente-Napimoga JT, et al. The flavonoid quercetin inhibits titanium dioxide (TiO2)-induced chronic arthritis in mice. J Nutr Biochem. 2018;53:81.

24. Li XP, Yu MX, Kuang TR, Yan X, Li CY, Hao HJ. Research progress on the anti-tumor effect of flavonoid derivatives. Acta Pharm Sinica. 2021;56:913–23.

25. Cui R, Liu H, Liu J, Ruan Z, Zhai GY. Research progress on therapeutic potential of quercetin. J Chin Materia Med. 2021;46:9.

26. Wang X, Li L, Liu JH, Yu BY. UPLC-UV method for determination of artemisinin in Artemisia annua from different habitats. Chin Wild Plant Res. 2012;31:28–31.

27. Lin YR. On the flora of the genus Artemisia in the world. Plant Res. 1995;15:31–37.

28. Yue YX, Shi BL, Zhang PF, Su JL, Li K, Yan SM. Research progress on the biological effects of Artemisia plants on animals. Chin J Anim Hub. 2015;51:79–82.

29. Ferreira JFS, Simon J, Janick J. Artemisia annua: botany, horticulture, pharmacology. Hor Rev. 1997;19:319.

30. Jastrzebska E, Wadas E, Daszkiewicz T. Nutritional value and health-promoting properties of mares milk. Czech J Anim Sci. 2017;62:511–8.

31. Li HL, Zhang AD, Qing GL, Mu Z, Sun J. Current status and prospects of research and utilization of Artemisia scoparia hydromethanolic extract. J Ethnopharmacol. 2013;145:18–24.

32. Wang XH, Ma MH, Zhang JT, Huang J, Nian H. Research progress on the pharmacological effects of Artemisia annua. Chin J Mod App Pharm. 2018;35:781–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions